Metalyse
Phase 3Small molecule
Boehringer IngelheimMetalyse is one of 66 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Lovenox
SanofiPhase 3
Lovenox
SanofiPhase 3
Byetta
AstraZenecaPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Xarelto
WWim Janssens
Phase 3
Allegra
CChattem
Phase 3
Rayaldee
OOrganon and Co
Phase 3
Unfractionated Heparin
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myocardial Infarction3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metalyse. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company